Loading...
XJPX2385
Market cap19mUSD
Dec 30, Last price  
119.00JPY
1D
1.71%
1Q
-15.00%
Jan 2017
-56.88%
Name

Soiken Holdings Inc

Chart & Performance

D1W1MN
XJPX:2385 chart
P/E
—
P/S
0.60
EPS
—
Div Yield, %
4.22%
Shrs. gr., 5y
—
Rev. gr., 5y
-7.38%
Revenues
5.16b
-36.16%
2,547,236,0001,980,355,0001,443,912,0001,520,121,0001,548,483,0001,966,277,0002,342,997,0002,548,899,0003,213,081,0004,147,858,0005,455,043,0007,568,171,0009,312,499,0008,942,496,0009,347,879,0008,079,926,0005,158,458,000
Net income
-662m
L
-95,927,000-163,078,000-1,145,236,000-284,987,000-184,141,00069,549,00026,025,000-5,519,00046,709,000186,569,000197,978,000553,467,000731,686,000562,061,000809,710,000451,847,000-662,203,000
CFO
-881m
L+767.34%
66,822,000-208,347,000-631,740,000-212,167,000-207,148,00086,363,000-65,191,000-71,883,000190,561,000133,500,000-74,034,000469,427,000829,558,000-107,441,0002,135,970,000-101,554,000-880,822,000
Dividend
Jun 27, 20245 JPY/sh

Profile

Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for physician-led pharmaceutical clinical research, health checkups, and specific health guidance; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.
URL
https://www.soiken.com/
IPO date
Dec 18, 2003
Employees
100
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
5,158,458
-36.16%
8,079,926
-13.56%
9,347,879
4.53%
Cost of revenue
2,676,085
7,333,339
8,122,283
Unusual Expense (Income)
NOPBT
2,482,373
746,587
1,225,596
NOPBT Margin
48.12%
9.24%
13.11%
Operating Taxes
48,388
269,646
435,345
Tax Rate
1.95%
36.12%
35.52%
NOPAT
2,433,985
476,941
790,251
Net income
(662,203)
-246.55%
451,847
-44.20%
809,710
44.06%
Dividends
(131,452)
(130,213)
(129,944)
Dividend yield
3.01%
1.66%
1.48%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
(307,374)
(534,015)
Long-term debt
Deferred revenue
Other long-term liabilities
5,080
17,246
16,357
Net debt
(4,801,489)
(6,273,966)
(6,572,006)
Cash flow
Cash from operating activities
(880,822)
(101,554)
2,135,970
CAPEX
(14,599)
(39,528)
(44,577)
Cash from investing activities
(14,292)
160,368
(244,577)
Cash from financing activities
(260,715)
(130,213)
(129,944)
FCF
1,835,059
(205,654)
2,534,655
Balance
Cash
4,790,024
5,945,854
6,217,253
Long term investments
11,465
20,738
(179,262)
Excess cash
4,543,566
5,562,596
5,570,597
Stockholders' equity
4,292,143
5,273,261
4,948,410
Invested Capital
1,962,046
1,564,958
1,090,004
ROIC
138.02%
35.93%
46.06%
ROCE
39.62%
10.92%
20.29%
EV
Common stock shares outstanding
26,158
26,158
26,158
Price
167.00
-44.33%
300.00
-10.71%
336.00
-26.32%
Market cap
4,368,419
-44.33%
7,847,460
-10.71%
8,789,155
-26.32%
EV
(416,831)
1,776,856
2,416,717
EBITDA
2,509,175
771,365
1,249,441
EV/EBITDA
2.30
1.93
Interest
Interest/NOPBT